HOWL Overview

Clene Inc. Gains: Clene Inc. shares rose 8.53% in after-hours trading after announcing an upcoming investor call regarding its CNM-Au8 program for ALS, despite a regular session decline.

Werewolf Therapeutics Update: Werewolf Therapeutics saw a 6.12% increase after hours, likely influenced by investor reactions to its recent presentation at a cancer immunotherapy conference, despite no new news.

Biomea Fusion Presentation: Biomea Fusion's stock climbed 7.31% after hours following its announcement of an upcoming presentation on icovamenib data at a major diabetes and cardiovascular disease congress.

General Market Trends: Other biotech companies like Denali Therapeutics, TScan Therapeutics, and Nyxoah also experienced after-hours gains, reflecting ongoing investor interest and positioning ahead of regulatory milestones and presentations.

Biotech Stocks Surge: Several biotech and life sciences companies experienced significant gains in after-hours trading on November 26, indicating strong investor interest despite a lack of major news.

Modular Medical's Approval: Modular Medical, Inc. saw an 11.51% increase in share price after receiving Institutional Review Board approval for its Pivot insulin delivery system study, which aims to gather critical data on device usability.

Standard BioTools Collaboration: Standard BioTools Inc. advanced 4.90% following a strategic partnership announcement with Molecular Instruments to enhance protein imaging capabilities through next-generation Imaging Mass Cytometry workflows.

Ongoing Investor Optimism: Companies like Werewolf Therapeutics, Cogent Biosciences, and Longeveron also reported gains, reflecting continued investor confidence in their research and development efforts, despite no new corporate updates.

Fast Track Designation: Werewolf Therapeutics has received Fast Track Designation from the FDA for WTX-124, aimed at treating patients with advanced cutaneous melanoma after standard immunotherapy, based on promising clinical data.

WTX-124 Therapy: WTX-124 is a conditionally activated IL-2 therapy designed to enhance anti-tumor immune responses while minimizing systemic side effects, currently being evaluated in a Phase 1/1b study alongside pembrolizumab for various advanced solid tumors.

Cassava Sciences Surge: Cassava Sciences (SAVA) saw a 37.1% increase in after-hours trading, driven by renewed interest in its investigational drug simufilam for TSC-related epilepsy, following positive preclinical data and leadership changes.

Helius Medical Technologies Rebound: Helius Medical Technologies (HSDT) rose 15.67% after announcing a $500 million private placement to pivot towards a Solana-focused treasury vehicle, while also advancing its medical device pipeline.

Werewolf Therapeutics Gains: Werewolf Therapeutics (HOWL) increased by 9.78% in after-hours trading, supported by interest in its INDUKINE platform and upcoming interim data from its lead candidate targeting advanced solid tumors.

Aytu BioPharma and Equillium Updates: Aytu BioPharma (AYTU) rose 7.63% ahead of its fiscal results announcement, while Equillium (EQ) gained 10.34% after securing financing to advance its novel drug EQ504 and progressing its lead candidate in clinical trials.